Thrombosis Research
Volume 124, Issue 4 , Pages 439-446 , September 2009

Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells

  • Amandine Jaulmes

      Affiliations

    • Division of Angiology, Servier Research Institute, 11 rue des Moulineaux, Suresnes 92150, France
    • ,
  • Patricia Sansilvestri-Morel

      Affiliations

    • Division of Angiology, Servier Research Institute, 11 rue des Moulineaux, Suresnes 92150, France
    • ,
  • Gaëlle Rolland-Valognes

      Affiliations

    • Division of Molecular Pharmacology & Physiopathology, Servier Research Institute, 125 chemin de ronde, Croissy sur Seine 78290, France
    • ,
  • Fabienne Bernhardt

      Affiliations

    • Division of Angiology, Servier Research Institute, 11 rue des Moulineaux, Suresnes 92150, France
    • ,
  • Roger Gaertner

      Affiliations

    • Division of Angiology, Servier Research Institute, 11 rue des Moulineaux, Suresnes 92150, France
    • ,
  • Brian P. Lockhart

      Affiliations

    • Division of Molecular Pharmacology & Physiopathology, Servier Research Institute, 125 chemin de ronde, Croissy sur Seine 78290, France
    • ,
  • Alex Cordi

      Affiliations

    • Division of Chemistry, Servier Research Institute, 11 rue des Moulineaux, Suresnes 92150, France
    • ,
  • Michel Wierzbicki

      Affiliations

    • Division of Chemistry, Servier Research Institute, 11 rue des Moulineaux, Suresnes 92150, France
    • ,
  • Alain Rupin

      Affiliations

    • Division of Angiology, Servier Research Institute, 11 rue des Moulineaux, Suresnes 92150, France
    • ,
  • Tony J. Verbeuren

      Affiliations

    • Division of Angiology, Servier Research Institute, 11 rue des Moulineaux, Suresnes 92150, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 55722518; fax: +33 1 55722430.

Received 15 January 2009 ,Revised 15 April 2009 ,Accepted 20 May 2009.

References 

  1. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction–the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost. 1998;80:749–756
  2. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke. 2000;31:26–32
  3. Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev. 2000;16:192–201
  4. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation. 1999;99:2496–2498
  5. Loskutoff DJ, Sawdey M, Keeton M, Schneiderman J. Regulation of PAI-1 gene expression in vivo. Thromb Haemost. 1993;70:135–137
  6. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840–844
  7. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation. 2003;108:2034–2040
  8. Rueckschloss U, Duerrschmidt N, Morawietz H. NADPH oxidase in endothelial cells: impact on atherosclerosis. Antioxid Redox Signal. 2003;5:171–180
  9. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494–501
  10. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OT. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol. 1996;271:H1626–H1634
  11. Bayraktutan U, Blayney L, Shah AM. Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:1903–1911
  12. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol. 2004;4:181–189
  13. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313
  14. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation. 2001;104:1767–1772
  15. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 2004;109:227–233
  16. Swiatkowska M, Szemraj J, Al-Nedawi KN, Pawlowska Z. Reactive oxygen species upregulate expression of PAI-1 in endothelial cells. Cell Mol Biol Lett. 2002;7:1065–1071
  17. Cheng JJ, Chao YJ, Wung BS, Wang DL. Cyclic strain-induced plasminogen activator inhibitor-1 (PAI-1) release from endothelial cells involves reactive oxygen species. Biochem Biophys Res Commun. 1996;225:100–105
  18. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol. 2005;25:519–525
  19. Rothe G, Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′-dichlorofluorescin. J Leukoc Biol. 1990;47:440–448
  20. Pasten C, Olave NC, Zhou L, Tabengwa EM, Wolkowicz PE, Grenett HE. Polyphenols downregulate PAI-1 gene expression in cultured human coronary artery endothelial cells: molecular contributor to cardiovascular protection. Thromb Res. 2007;121:59–65
  21. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006;26:2200–2207
  22. Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005;111:343–348
  23. Muscoli C, Cuzzocrea S, Riley DP, Zweier JL, Thiemermann C, Wang ZQ, et al. On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol. 2003;140:445–460
  24. Yoshida LS, Tsunawaki S. Expression of NADPH oxidases and enhanced H(2)O(2)-generating activity in human coronary artery endothelial cells upon induction with tumor necrosis factor-alpha. Int Immunopharmacol. 2008;8:1377–1385
  25. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R277–R297
  26. Hancock JT, Jones OT. The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages. Biochem J. 1987;242:103–107
  27. Cayatte AJ, Rupin A, Oliver-Krasinski J, Maitland K, Sansilvestri-Morel P, Boussard MF, et al. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler Thromb Vasc Biol. 2001;21:1577–1584
  28. Park HS, Chun JN, Jung HY, Choi C, Bae YS. Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. Cardiovasc Res. 2006;72:447–455
  29. Ding H, Hashem M, Triggle C. Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS. Eur J Pharmacol. 2007;561:121–128
  30. Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, et al. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia. 2003;46:1428–1437
  31. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000;20:2175–2183
  32. Hamaguchi E, Takamura T, Shimizu A, Nagai Y. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J Pharmacol Exp Ther. 2003;307:987–994
  33. Norata GD, Banfi C, Pirillo A, Tremoli E, Hamsten A, Catapano AL, et al. Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. Br J Haematol. 2004;127:97–104
  34. McCubrey JA, Lahair MM, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal. 2006;8:1775–1789
  35. Yu W, Akishita M, Xi H, Nagai K, Sudoh N, Hasegawa H, et al. Angiotensin converting enzyme inhibitor attenuates oxidative stress-induced endothelial cell apoptosis via p38 MAP kinase inhibition. Clin Chim Acta. 2006;364:328–334
  36. Cuda G, Paterno R, Ceravolo R, Candigliota M, Perrotti N, Perticone F, et al. Protection of human endothelial cells from oxidative stress: role of Ras-ERK1/2 signaling. Circulation. 2002;105:968–974
  37. Cheng Y, Qiu F, Ye YC, Guo ZM, Tashiro S, Onodera S, et al. Autophagy inhibits reactive oxygen species-mediated apoptosis via activating p38-nuclear factor-kappa B survival pathways in oridonin-treated murine fibrosarcoma L929 cells. FEBS J. 2009;276:1291–1306
  38. Bonello S, Zahringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, et al. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol. 2007;27:755–761

PII: S0049-3848(09)00257-6

doi: 10.1016/j.thromres.2009.05.018

Thrombosis Research
Volume 124, Issue 4 , Pages 439-446 , September 2009

Article Tools

* Image Usage & Resolution